Oakworth Capital Inc. Purchases 1,452 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Oakworth Capital Inc. grew its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 15.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 11,127 shares of the company’s stock after buying an additional 1,452 shares during the period. Oakworth Capital Inc.’s holdings in Harmony Biosciences were worth $383,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of HRMY. GAMMA Investing LLC grew its position in shares of Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after acquiring an additional 436 shares during the period. Mendota Financial Group LLC boosted its holdings in shares of Harmony Biosciences by 24,125.0% during the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after buying an additional 965 shares during the period. CWM LLC boosted its holdings in shares of Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after buying an additional 775 shares during the period. KBC Group NV boosted its holdings in shares of Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after buying an additional 819 shares during the period. Finally, Quantbot Technologies LP bought a new stake in shares of Harmony Biosciences during the 3rd quarter worth about $74,000. Institutional investors own 86.23% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on HRMY shares. Mizuho lifted their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Raymond James reaffirmed an “outperform” rating and set a $40.00 target price on shares of Harmony Biosciences in a report on Thursday, October 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a report on Monday, January 13th. Oppenheimer reiterated an “outperform” rating and issued a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Harmony Biosciences in a research note on Monday, January 27th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $55.00.

Insider Activity

In related news, insider Jeffrey Dierks sold 10,507 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jeffrey M. Dayno sold 19,293 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total transaction of $774,228.09. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,452 shares of company stock worth $2,831,679. 30.80% of the stock is currently owned by corporate insiders.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $39.36 on Thursday. The firm has a 50 day moving average of $35.66 and a 200-day moving average of $35.42. The stock has a market capitalization of $2.24 billion, a PE ratio of 18.65, a PEG ratio of 0.51 and a beta of 0.80. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.